Bristol Myers Squibb stock falls 1.77 percent after Q2 gains fade
Published on 09/24/2026 at 11:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock fell 1.77 percent to USD 61.15 at the NYSE close on September 23, 2026. The move came after a strong second quarter in which revenue rose 5.7 percent year over year to USD 12.973 billion, keeping the pharmaceutical group tied to execution rather than a single product story.
Q2 earnings beat expectations
According to MarketBeat, Bristol Myers Squibb reported adjusted EPS of USD 2.04 for Q2 2026, above the USD 1.60 consensus estimate. Revenue of USD 12.97 billion also exceeded the USD 11.74 billion estimate, providing a quantified earnings comparison behind the company narrative.
The earnings profile was broader than the headline beat. The company generated USD 3.393 billion in operating cash flow during Q2 2026, compared with USD 1.104 billion in Q1 2026, while diluted GAAP EPS rose to USD 1.62 from USD 1.31 between those quarters.
Growth portfolio carries the mix
The Q2 2026 growth portfolio rose 14 percent to USD 7.6 billion, according to the Perplexity Finance earnings transcript. Eliquis revenue increased 21 percent to USD 4.5 billion, while Camzyos revenue climbed 59 percent to USD 416 million.
Management raised full-year 2026 revenue and adjusted EPS guidance after the first-half performance. The outlook includes Eliquis growth of 20 percent to 25 percent and a legacy portfolio decline of 4 percent to 6 percent, making the balance between newer medicines and older products the key operating comparison.
Next results date is set
As Yahoo Finance reported on September 18, 2026, Bristol Myers Squibb will report third-quarter 2026 results on October 29, 2026. That date gives the market a defined checkpoint for testing whether the 14 percent growth-portfolio expansion and the raised full-year outlook are holding.
Stock remains below yearly high
Bristol Myers Squibb traded at USD 61.15 on the NYSE on September 23, 2026, down USD 1.10 from the prior close. Its 52-week range was USD 42.52 to USD 68.64, placing the stock USD 7.49 below the yearly high, while market capitalization stood at USD 124.912 billion.
Bristol Myers Squibb stock at a glance
- Company: Bristol-Myers Squibb Company
- Ticker: BMY
- Trading venue: NYSE
- Closing price (September 23, 2026): USD 61.15
- Market capitalization: USD 124.912 billion (as of September 23, 2026)
- 52-week range: USD 42.52-68.64
- Sector / Industry: Healthcare / Drug Manufacturers - General
